{"title": "Steven Deeks  UCSF Profiles", "author": null, "url": "https://profiles.ucsf.edu/steven.deeks", "hostname": "ucsf.edu", "description": "Steven Deeks's profile, publications, research topics, and co-authors", "sitename": "UCSF", "date": "2002-09-01", "cleaned_text": "- Adaptation of Droplet Digital PCR-Based HIV Transcription Profiling to Digital PCR and Association of HIV Transcription and Total or Intact HIV DNA. Viruses. 2023 Jul 22; 15(7). Tumpach C, Rhodes A, Kim Y, Ong J, Liu H, Chibo D, Druce J, Williamson D, Hoh R, Deeks of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. [Sarvadhavabhatla S](https://profiles.ucsf.edu/sannidhi.sarvadhavabhatla), latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. J Clin Invest. 2023 Jul 18. McMyn NF, Varriale J, Fray Zitzmann C, MacLeod HJ, Singhal A, Moskovljevic M, Garcia MA, Lopez BM, Hariharan V, misclassified defective proviruses on HIV reservoir measurements. Nat Commun. 2023 Jul human blood innate lymphoid cell subsets sheds light on HIV-1 pathogenesis. EMBO J. 2023 Jun 29; e114153. Wang NJ, Mintzer StLouis on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. PLoS One. 2023; 18(6):e0286297. Horwitz LI, Thaweethai T, Brosnahan Goldman [Jacoby VL](https://profiles.ucsf.edu/vanessa.jacoby), Jordan MR, Krishnan Laiyemo AO, L, Patzer RE, Sekar A, Singer NG, Stiles LE, Taylor BS, Ahmed S, Algren HA, Anglin Aponte-Soto L, Ashktorab H, C, Bind MC, Black LJ, Blomkalns AL, Brim H, Castro M, Chan J, Charney AW, Chen BK, Chen LQ, Chen P, Chestek D, Chibnik LB, Chow DC, Chu Clifton J, V, Gallagher EJ, Granger JP, Greenway FL, Hafner JW, Han JE, Harkins MS, Hauser KSP, Heath JR, Hernandez CR, Ho O, Hoffman MK, Hoover SE, Horowitz CR, Hsu H, [Hsue PY](https://profiles.ucsf.edu/priscilla.hsue), Hughes BL, Jagannathan P, James JA, John S, Judd SE, Juskowich JJ, Kanjilal DG, Karlson EW, Katz SD, Luciano Lutrick SK, G, Maranga Vasey A, Vernon SD, Vidal C, Walker T, Ward HD, Warren DE, Weeks RM, Weiner SJ, Weyer JC, Wheeler JL, Whiteheart SW, and cure of HIV infection. Nat Rev Microbiol. 2023 Jun 21. of Culturable-Virus Detection and Household Transmission of SARS-CoV-2, California and Tennessee, 2020-2022. J Infect S, Singh TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Alba GA, Alicic R, Altman N, Anglin K, Argueta U, Ashktorab H, Baslet G, Bassett IV, Bateman L, Bedi B, Bhattacharyya S, Bind MA, Blomkalns AL, Bonilla H, Bush PA, Castro M, Chan J, Charney AW, Chen P, Chibnik LB, J, Fonseca V, N, V, Gander JC, Gardner EM, Geng LN, Gibson KS, Go JD, Grebe H, Greenway Habli M, Hafner J, Han JE, Hanson KA, Heath J, Hernandez C, Hess R, Hodder SL, Hoffman MK, Hoover SE, [Huang B](https://profiles.ucsf.edu/beatrice.huang), Hughes BL, Jagannathan P, John J, Jordan MR, Katz SD, Kaufman ES, Kelly JD, [Kelly SW](https://profiles.ucsf.edu/john.d.kelly), Kemp Lanca M, Lee-Iannotti JK, Logarbo BP, Longo MT, Luciano CA, K, Maley JH, Marathe JG, Marconi Quigley JG, Reddy U, Reece R, Reeder H, Reeves WB, Reiman Wallace ZS, Ward HD, Warren DE, Weiner SJ, Welch S, Whiteheart SW, Wiley Z, Wisnivesky JP, Yee LM, Zisis a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight. 2023 06 08; 8(11). [Bodansky chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID. J Infect Dis. 2023 May 11. [Durstenfeld MS](https://profiles.ucsf.edu/matthew.durstenfeld), [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Kaveti VM, Lu of SARS-CoV-2 Infection and Cardiopulmonary Long COVID with Exercise Capacity and Chronotropic Incompetence among People with HIV. medRxiv. 2023 May Platform for Antibody Responses to Infection. Pathogens. 2023 May 02; 12(5). Byrum JR, IE, Forst ML, Li H, Larson AG, Blackmon L, Liu Z, Wu W, Ahyong V, bioRxiv. 2023 May 01. Deere JD, Merriam D, Leggat KM, Chang WW, M\u00e9ndez-Lagares G, Kieu H, Dutra J, Fontaine J, Lu W, Chin N, Chen C, Tran BC, Salinas J, Miller CN, Deeks SG, Lifson Scales: A Framework for Unbiased Estimation of Cumulative Incidence Incorporating Antibody Kinetics and Epidemic Recency. Am J Epidemiol. 2023 Apr 29. Takahashi S, [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Hakim J, Turcios K, cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. J Exp Med. 2023 Jul 03; 220(7). Sengupta S, Zhang J, Reed MC, Yu Boronina TN, Board NL, for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Ther. 2023 Apr; 30(3-4):405. Adair JE, Androski Dee L, Deeks S, Draz M, Dub\u00e9 K, Dybul M, Gurkan U, Harlow E, Kityo C, Louella M, Malik P, Mathews V, McKemey Viremia. medRxiv. 2023 Mar 31. Mohammadi Etemad Zhang Li Y, Bedwell GJ, Sharaf R, A, Melberg M, Wong Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Anderson PL, Deeks SG, Lederman MM, Yawetz of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms. medRxiv. 2023 Mar 31. Buck AM, [Deitchman AN](https://profiles.ucsf.edu/amelia.deitchman), Takahashi Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy. Front Immunol. 2023; 14:1123342. Chiu CY, Schou exercise chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID. medRxiv. 2023 Mar 21. [Durstenfeld MS](https://profiles.ucsf.edu/matthew.durstenfeld), [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Kaveti P, Hill C, Li D, Swaminathan S, Arechiga VM, Lu S, [Goldberg SA](https://profiles.ucsf.edu/sarah.goldberg), manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv. 2023 Feb 10. Yin K, [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Thomas R, Shin MG, Neidleman J, Luo X, Hoh R, Anglin K, [Huang B](https://profiles.ucsf.edu/beatrice.huang), Argueta U, Lopez M, Valdivieso D, reveals a shared post-COVID signature in fully recovered and Long COVID patients. medRxiv. 2023 Feb 09. [Bodansky A](https://profiles.ucsf.edu/aaron.bodansky), Wang CY, Saxena A, Takahashi [Huang coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023 02 01; 133(3). [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), SE, Ryder F, Lu S, [Goldberg Rodriguez cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus. S, Zetterberg genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4. Front Immunol. 2023; 14:1064346. Fisher K, Schlub TE, Boyer Rasmussen Rhodes A, Hoh R, [Hecht FM](https://profiles.ucsf.edu/frederick.hecht), of tumor suppressor, innate immune, inflammasome, and potassium/gap junction channel host genes significantly predict viral reservoir size during treated HIV infection. bioRxiv. 2023 Jan 12. Dwivedi AK, Siegel DA, [Thanh C](https://profiles.ucsd.edu/cassandra.thanh), Hoh R, F](https://profiles.ucsf.edu/frederick.hecht), [Pilcher C](https://profiles.ucsf.edu/christopher.pilcher), Milush J, Busch Stone M, Roychoudhury P, of Interferon Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID. J Infect Dis. 2023 01 11; 227(2):246-250. [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Mitchell T cells are disproportionately spared in ART-suppressed HIV. bioRxiv. 2023 Jan 07. [Ogongo P](https://profiles.ucsf.edu/paul.ogongo), HIV silencing and cell survival signatures in infected T cell reservoirs. Nature. 2023 02; 614(7947):318-325. Clark IC, Mudvari P, Thaploo S, Smith S, Abu-Laban M, Hamouda M, Theberge M, Shah S, Ko SH, P\u00e9rez L, Bunis DG, Lee JS, Kilam D, Zakaria S, Choi S, Darko S, Henry AR, Wheeler MA, Hoh R, Butrus Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe. 2023 01 11; 31(1):83-96.e5. Lian X, Seiger KW, Parsons EM, Gao C, Sun W, Gladkov GT, Roseto IC, Einkauf KB, Osborn MR, Chevalier C, Blackmer J, Carrington M, Rosenberg ES, Lederman MM, McMahon DK, Bosch RJ, Jacobson JM, Gandhi J Virol. 2023 01 31; 97(1):e0125422. Melberg M, Etemad Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral Therapy-Suppressed Individuals. J Virol. 2022 Moron-Lopez I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict [Pillai Stone M, Levy CN, Huang ML, Hladik CD4+ T-cell subsets in antiretroviral therapy-suppressed people with HIV. 02 01; 37(2):247-257. Gartner MJ, Tumpach C, Dantanarayana A, Angelovich TA, Anderson JL, Symons SG, Flynn JK, Willingness of Racially Diverse Young Adults Living with HIV to Participate in HIV Cure Research: A Cross-Sectional Survey in the United States. AIDS Res Hum Retroviruses. 2022 Nov early 08; 7(21). Anthony-Gonda K, Ray A, Su H, Wang Y, Xiong Y, Lee D, Block A, Chilunda V, Weiselberg J, Zemelko L, Wang YY, Kleinsorge-Block S, JS, Lima Ochsenbauer Dimitrov DS, Orentas R, Deeks Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for Infection and Infectious Viral Shedding. Open Forum Infect Dis. 2022 Nov; 9(11):ofac563. Mathur A, on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis. 2022 10 12; 75(8):1389-1396. Scully EP, Aga E, Tsibris N, K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu V, [Sarvadhavabhatla S](https://profiles.ucsf.edu/sannidhi.sarvadhavabhatla), Beltran F, Gill G, Lynch K, Yun C, [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Hoh R, [Henrich that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency. Cell Rep Med. 2022 10 18; 3(10):100766. Rasmussen TA, JM, A, McMahon JH, Lau JSY, Chang JJ, Gubser C, Brown W, Hoh R, Krone M, Pascoe R, Chiu CY, Bramhall M, Lee HJ, Haque A, Fromentin R, Chomont N, Milush J, Van der Sluis RM, Palmer S, Deeks SG, Cameron PU, Evans Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission: A Longitudinal Cohort A, K, MC, Romero M, Diaz Sanchez R, Djomaleu M, Mathur S, Chen JY, of Koshy J, Hong KY, Rasmussen H, Miller GE, Bishehsari F, Balk RA, Moy JN, Hoh R, Lu S, Goldman AR, Tang longitudinal [Shak S, J, the Latent HIV Reservoir. mBio. 2022 10 26; 13(5):e0189122. Packard TA, Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. of Koshy J, Hong KY, Rasmussen H, Miller GE, Bishehsari F, Balk RA, Moy JN, Hoh R, Lu S, Goldman AR, Tang HY, Chenna A, Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. Front Immunol. 2022; 13:924718. Freeman ML, Clagett BM, Moisi D, Yeh Morris CD, Ryu Stein JH, of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID. medRxiv. 2022 [Peluso of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. Front Immunol. 2022; 13:945706. Valentin C, Rosati Angel Burns R, Agarwal M, Gergen J, Petsch B, Oostvogels L, immune responses in people with HIV recovering from SARS-COV-2 infection. Mentions: - Plasma Markers of Neurologic Injury and in People With Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine. 2022 Jun; 80:104072. Serrano-Villar inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms V, Sun K, Shao S, Hill C, [Arreguin MI](https://profiles.ucsf.edu/mireya.arreguin), Lu S, Hoh R, Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy. J Infect Dis. 2022 05 16; 225(10):1721-1730. Stern J, Solomon T cell mitochondrial function J Clin Invest. 2022 05 AA, Ghneim Noel-Romas Rodriguez B, (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. EBioMedicine. 2022 Jun; 80:104037. Luo Z, Health SL, Li M, Yang H, Wu Y, Collins M, Deeks SG, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), Scott Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Res Hum Retroviruses. 2022 06; Simoni JM, Sugarman J, Brown B, [Sauceda JA](https://profiles.ucsf.edu/john.sauceda), Henley L, Deeks S, Fox L, and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. BMC Med Ethics. 2022 04 09; 23(1):39. Dub\u00e9 K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, Dee L, Taylor RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial. Trials. 2022 Apr 05; 23(1):263. Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, Ashraf A, Jacob M, Cole T, Hurley L, Pace M, Ogbe A, Khan M, Zacharopoulou P, Brown H, Sutherland E, Box H, Fox J, Deeks S, Horowitz J, Nussenzweig reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. J Clin Invest. 2022 FG, Mathivanan V, Horsburgh BA, Fisher K, Tong O, Lee E, Ahn H, Shaik A, Fromentin R, Hoh R, Bacchus-Souffan C, Nasr N, Turville SG, Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. J Infect Dis. 2022 04 01; 225(7):1168-1178. Horsburgh BA, Hiener B, Fisher K, Lee E, Morgan H, Eden JS, von Stockenstrom S, Odevall 2022 23; 96(6):e0201121. Fisher K, Wang XQ, Lee A, Morcilla V, de Vries A, Lee E, Eden JS, Deeks SG, Kelleher Nixon CC, Iyer Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2022 MacLaren Keefer Barr L, Acosta E, Ananworanich J, Coombs R, Mellors JW, Landay AL, infection lowers tissue vDNA, rescues immune function, and overall health. JCI Phenotypes Vary by the pandemic requires a global approach to understanding the heterogeneity of vaccine responses. Nat Immunol. strategies to safely conduct HIV treatment research in the context of COVID-19. J Int AIDS Soc. 2022 02; 25(2):e25882. Henderson M, Fidler S, Mothe Collins and Lymphoid T and NK Cells From HIV+ J, Thomas R, Shin latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med. 2022 01 26; Cheever and abnormal cerebrospinal fluid associate with cognitive symptoms after mild and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Dis. 2022 J, Rugart PR, Chen Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi Weiss JO, Mehdi I, Pineda-Ramirez Tang AF, Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Sci Transl Med. 2021 12 15; 13(624):eabl4097. Lian X, Gao C, C, Einkauf KB, Seiger KW, E, for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021 12; 27(12):2085-2098. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR, International AIDS Society (IAS) Global Scientific Strategy working Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2021 12 AB, Reed JS, Bashirova AA, KB, McDonald E, Wu HL, a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. J Infect Dis. 2021 11 16; 224(9):1593-1598. Wu HIV-1 Infection on Angiopoietin 1 and 2 Levels and Measures of Microvascular and Macrovascular Endothelial Dysfunction. AB](https://profiles.ucsf.edu/anjali.thakkar), Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. AIDS. 2021 11 01; 35(13):2225-2227. Fajnzylber Henry K, Tebas P, S, Chun TW, for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States. AIDS Res Ther. 2021 10 18; 18(1):75. Dub\u00e9 K, Kanazawa J, Dee Taylor J, Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. J Infect Dis. 2021 10 13; 224(7):1209-1218. Stone M, Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021 10 05; 73(7):e1973-e1981. Rasmussen Rajdev Rhodes estimation incorporating antibody kinetics and epidemic recency. medRxiv. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Ther. 2023 04; 30(3-4):216-221. Adair JE, Androski Dee L, Deeks S, Draz M, Dub\u00e9 K, Dybul M, Gurkan U, Harlow E, Kityo C, Louella M, Malik P, Mathews V, McKemey CD8+ T cells precedes aborted spontaneous control of viremia. Newman Ly NL, Lian X, Rull Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. Front Immunol. 2021; 12:740395. Kammers K, Chen A, Monaco DR, Hudelson SE, Grant-McAuley W, Moore RD, Alter G, Deeks SG, Morrison CS, Eller LA, immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021 Context of Ongoing HIV Cure-Related Research Studies. J Shao detectability are driven by disease severity, Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infect vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci Transl Med. 2021 06 23; 13(599). SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, M, Deeks SG. PMID: 34162752. - Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. J Infect Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Dee L, Shao S, Taylor J, Campbell D, Collins S, [Gandhi M](https://profiles.ucsf.edu/monica.gandhi), Johnston antibody responses to SARS-CoV-2 infection. medRxiv. 2021 May 11. Byrum JR, Lower Socioeconomic Status Associates With Greater Systemic and Arterial Inflammation in HIV. J Acquir Moore Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. AIDS Res Hum Retroviruses. 2022 02; 38(2):127-130. MacDonald DM, Collins G, Wendt Tracy RP, Rhame F, Deeks SA, Temesgen Profiles HIV-1 Pro-Viral DNA in Individuals on ART. Viruses. 2021 04 29; 13(5). Boltz remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. Cell assay to measure the intact HIV-1 proviral reservoir. Cell Rep Med. 2021 04 20; Hughes SM, Roychoudhury P, Reeves DB, Amstuz C, Zhu H, Huang ML, Wei Y, Bull ME, Cassidy NAJ, McClure J, Frenkel to inform the study of post-acute sequelae and recovery: a disease. AIDS. 2021 03 15; Wolfson Liappis Rizza study of post-acute sequelae J, Rugart PR, Chen Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi Weiss JO, Mehdi I, Pineda-Ramirez Tang AF, magnitude and detectability are driven by disease severity, and assay. medRxiv. 2021 Mar 05. [Peluso SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. medRxiv. 2021 Mar 01. [Peluso Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following Dantanarayana A, Gooey M, Anderson J, [Bacchetti P](https://profiles.ucsf.edu/peter.bacchetti), Deeks SG, McMahon J, and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker AIDS Res Hum Retroviruses. B, [Sauceda JA](https://profiles.ucsf.edu/john.sauceda), Deeks S, Fox L, Gandhi RT, Complications and Neurological Manifestations. Cells. 2021 02 13; 10(2). Sun B, Tang Wang L, Raymond KA, Starke CE, Mudd JC, Chen W, Smullin C, Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex HS, Hull PA, Montano M, Migueles SA, Rosenthal D, Hogan LE, Johnson JR, Packard TA, Grimmett ZW, Herzig E, Besnard E, Nekorchuk M, CD4+ T H, Soroosh GP, Duan J, Rhodehouse K, Hill AL, Beg SA, McCormick K, Raymond HE, Nobles CL, Everett JK, Kwon KJ, White JA, Lai of peripheral blood reveals an epigenetic signature associated with severe COVID-19. J 110(1):21-26. Corley Seethamraju H, Bram Y, [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Torres L, Iyer NS, Premeaux TA, CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathog. Hoh R, Stone M, Hiatt J, Kim P, Chopra A, Ahn H, York DL, [Hecht Coinfections, and Complications: Summary and Recommendation for Syndr. 2021 E, Justice A, Sacktor PW](https://profiles.ucsf.edu/peter.hunt), and Methamphetamine Use. Curr HIV Res. 2021; Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells. J Virol. 2020 12 22; 95(2). [Yukl SA](https://profiles.ucsf.edu/steven.yukl), Khan S, Chen TH, Trapecar M, F, Xie G, Telwatte S, Fulop D, HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper. J Virus Erad. Vanderkerckhove L, Collins S, Kelly D, J, - The case for an HIV cure and how to get there. Lancet HIV. 2021 01; 8(1):e51-e58. Dybul on a target product profile for an HIV cure. Lancet HIV. 2021 01; 8(1):e42-e50. Lewin Dybul M, JM](https://profiles.ucsf.edu/mike.mccune), I, Nsubuga M, Warren Viremia in Individuals on Therapy. J Clin Microbiol. 2020 18; underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. AIDS. 2020 11 15; 34(14):2013-2024. Telwatte Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842. Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. Open Forum Infect Dis. HIV control. Proc Natl Sci U S A. 2020 Viard Haas D, Goedert JJ, Deeks SG, Fellay J, Walker B, Goulder P, Cresswell P, of HIV control and latent reservoir size. PLoS Pathog. 2020 10; 16(10):e1008868. Das H, Irrinki A, Pohlmeyer C, Min-Oo G, Lin S, Weiner JA, Cihlar T, Ackerman ME, Julg B, Deeks S, Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. JAMA Netw Open. HIV CD4 T cell reservoir. Elife. 2020 09 29; 9. Neidleman J, Luo X, [Frouard J](https://profiles.ucsf.edu/julie.frouard), Xie G, Hsiao F, Ma T, Morcilla V, Lee A, Telwatte S, Thomas R, Tamaki W, Wheeler B, Hoh State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging. AIDS Res Hum Retroviruses. 2020 12; individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2021 05; 21(5):1765-1779. [Henrich TJ](https://profiles.ucsf.edu/timothy.henrich), Schreiner transcription by inhibiting HIV-1 splicing and T cell activation. J Clin Invest. 2020 09 01; 130(9):4969-4984. Yeh YJ, Jenike KM, Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020 09; 585(7824):261-267. Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, Chen SMY, Hua S, Rhee antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. medRxiv. 2020 Aug DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proc Natl Acad Sci U S Simonetti FR, White JA, Tumiotto C, Ritter Deeks SG, Howell BJ, HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. J Clin Invest. 2020 07 01; 130(7):3543-3559. on HIV-Specific CD8 T Cells in Untreated HLA-B*57:01 Individuals Followed from Early Infection. J Virol. 2020 07 01; 94(14). Scharf L, Tauriainen Comorbidities in People with HIV: Highlights from the HIV HIV latency by suppressing ER stress in T cells. Nat Microbiol. 2020 09; 5(9):1144-1157. Vallejo-Gracia Battivelli E, Tezil T, Krey K, Raymond KA, Hull PA, Walter M, Habrylo I, The immune response fails to control HIV early in initial virus spread. J Clin Invest. 2020 therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. J aberrant host gene transcription as a potential therapeutic target. Sci Transl Med. 2020 05 13; 12(543). Liu S, Talbot CC, Mehta S, Albrecht K, Hao H, Zhang H, Pollack RA, Beg SA, Calvi RM, Hu J, Durand CM, Ambinder RF, Hoh T Cell Turnover To Reduce HIV-1 Reservoirs. Trends Immunol. 2020 06; 41(6):466-480. Grossman Z, Singh NJ, Simonetti F, Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. J The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. Cell Host Microbe. 2020 04 08; 27(4):519-530. of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies. AIDS. 2020 04 01; 34(5):659-668. Horsburgh BA, Lee E, Hiener B, Converging Approaches. Front Immunol. 2020; 11:519. Paiardini M, Dhodapkar maintain stem cell memory-associated epigenetic programs during type 1 diabetes. Nat Immunol. Abdelsamed HA, Zebley CC, Nguyen Ghoneim HE, Crawford JC, Alfei F, Alli S, Ribeiro SP, Castellaw AH, McGargill H, Boi SK, Speake C, Serti E, Turka LA, Busch ME, Stone M, Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. J Infect Dis. 2020 03 16; 221(7):1146-1155. and immune activation are associated with carotid intima-media thickness progression in treated HIV infection. AIDS. 2020 03 15; 34(4):519-528. Hsu DC, Ma YF, Narwan in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. J Virol. 2020 02 28; 94(6). Roche M, Tumpach C, Symons J, Gartner M, Anderson JL, Khoury G, Cashin K, Cameron PU, Churchill and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. J Virus 2020 Feb 20; Germanio multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. J Virus Erad. 2020 Feb 20; 6(1):34-37. [Peluso MJ](https://profiles.ucsf.edu/michael.peluso), Dee CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. J Infect Dis. 2020 02 18; 221(5):744-755. Anderson JL, Khoury G, W, cells. Immunol. McCauley S, Kucukural A, CD4+ T cell subsets show similar low inducibility of latent HIV-1 proviruses. Sci Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. J Virol. 2020 01 17; 94(3). Lee E, von Stockenstrom S, Morcilla V, Why and where an HIV cure is needed and how it might be achieved. Nature. 2019 12; Elite of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells. Sci Transl Med. 2019 12 18; 11(523). Nguyen S, Deleage S, Ransier Agarwal D, Japp Del Rio Estrada PM, Ablanedo-Terrazas Y, Gostick E, JA, Zhang Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proc Natl Acad Sci U Murrell B, Wiegand A, Spindler J, Raley C, Hautman HIV-1 Latency Reversal in Ribeiro Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Immunol. 2019 Nov; 20(11):1555. Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, SG, Haas DW, Michael B, S, Chowdhury Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform. Cell. 2019 10 31; 179(4):880-894.e10. Herzig E, Kim KC, Packard TA, Vardi N, Schwarzer R, Gramatica A, Deeks SG, Williams replication-competent HIV-l in resting CD4+ T cells Pathog. Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. J Acquir Immune Defic Syndr. 2019 Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. Front Microbiol. 2019; 10:2214. Lee E, [Bacchetti of single-copy assays when some observations are zero. J 18; elite control is associated with reduced TRAILshort expression. AIDS. 2019 09 01; 33(11):1757-1763. Paim Highly Stable on Antiretroviral Therapy. Mol Ther Methods Clin Dev. 2019 Dec 13; 15:9-17. Xu Trumble IM, Warren JA, Clutton G, Abad-Fernandez M, Kirchnerr J, - HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. J Clin Invest. 2019 07 30; Wu X, Keele BF, Milush JM, Hoh R, Mellors in HIV Remission Studies With Treatment Interruption: A Symposium. J Infect Dis. 2019 07 Analytical Treatment Interruptions in HIV Cure-Related Studies? J Infect Dis. 2019 07 outcome. Immunol. 2019 07; 20(7):824-834. Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, SG, Haas DW, Michael B, Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Front Immunol. 2019; 10:1021. Hutchinson JM, Mesa O'Rourke SM, Limoli and Myocardial Infarction in HIV -Infected Heart inter-lab assays of MP](https://profiles.ucsf.edu/michael.busch), of HIV+ controllers and their family members. Elife. 2019 04 09; 8. Gonzalo-Gil E, Rapuano PB, Ikediobi Leibowitz Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. J Virol. 2019 04 01; 93(7). Pohlmeyer CW, Gonzalez Deeks trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. Stat Med. 2019 06 15; 38(13):2428-2446. Caniglia EC, Robins JM, R, Abgrall S, Mugavero MJ, Hern\u00e1ndez-D\u00edaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, [Mathews Jarr\u00edn I, Alejos Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268. Julg B, Dee L, Ananworanich J, Barouch DH, Caskey M, Colby L, Dong KL, Dub\u00e9 K, Eron J, Frater J, Gandhi RT, Geleziunas Goulder P, Hanna GJ, Jefferys R, Johnston R, D, Li JZ, Likhitwonnawut van Lunzen J, Martinez-Picado Miller Nixon Salzwedel Salzwedel K, Schacker T, Sheikh V, S\u00f8gaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, JW, Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. J Infect Dis. 2019 03 15; 219(7):1084-1094. Scully Altfeld in CD4+ T cells ART-suppressed Nat A approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019 02; 566(7742):120-125. Bruner KM, Wang Z, Bender Sengupta Kufera JT, A, Nobles C, of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency. PLoS Pathog. 2019 01; 15(1):e1007498. Li Z, Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. J Acquir Immune Defic Acquir Immune RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin Cardiol. 2018 12 04; 72(22):2809-2811. [Hsue PY](https://profiles.ucsf.edu/priscilla.hsue), Li and differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963. Mitsuyasu R, [Schooley RT](https://profiles.ucsd.edu/robert.schooley), Henry K, Tebas P, there? of Disulfiram on Inducing Latent HIV-1 Transcription in a reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018 10 01; Li JZ, Hartig H, Bakkour S, Busch M, Alter G, Marty unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. AIDS. 2018 09 24; 32(15):2119-2128. Chang CC, Naranbhai V, Stern J, Roche M, Dantanarayana A, Ke R, Tennakoon S, Solomon A, Hoh R, Hartogensis W, [Hecht FM](https://profiles.ucsf.edu/frederick.hecht), Sikaris K, Price DJ, Elliott JH, Deeks SG, Churchill M, Cameron PU, CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 2018 09 22; 218(9):1394-1403. Lidofsky A, Holmes JA, Feeney ER, Kruger S, Zheng H, Seguin IS, Altinbas A, Curr Opin HIV AIDS. 2018 09; of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proc Natl Acad Sci U S A. 2018 08 14; Das B, Dobrowolski C, Luttge health impact of future HIV cure-related interventions through advance planning. J Virus Erad. 2018 Jul 01; 4(3):182-185. Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis. 2018 06 20; 218(2):239-248. Angelidou HIV-specific resident memory CD8+ T cells in human lymphoid tissue. Sci Immunol. 2018 06 01; 3(24). Buggert Oca G, Bengsch B, Darko S, Ransier A, Roberts ER, Del Alcazar Brody IB, Vella LA, Beura L, Wijeyesinghe RS, PM, Y, L, Sada Japp A, Manne Vartanian Huffman G, Frank mindfulness-based stress reduction in HIV latency reactivation in infected CD4+ MS, lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS 04; D, Del PM, Ablanedo-Terrazas Y, Noyan K, Reuter MA, Demers K, Sandberg JK, Eller MA, Streeck H, Jansson M, P, S\u00f6nnerborg variation modifies HLA-B*57 protection against HIV-1. J Clin Invest. 2018 05 01; 128(5):1903-1912. Martin MP, Naranbhai V, Shea PR, Qi Y, Ramsuran V, Vince N, Gao X, Thomas R, Brumme ZL, Migueles SA, Connors M, Michael N, Fellay J, Gostick E, Llewellyn-Lacey S, Price DA, Lafont BA, Pymm P, Saunders PM, Widjaja J, Wong SC, Vivian JP, the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? J Infect treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol. 2018 02 15; 92(4). Adland E, Hill M, Lavandier N, Csala Chen F, Radkowski JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS One. 2018; Cytotoxic Effector Molecules in Blood and Gastrointestinal of NKG2A-expressing cells. Science. 2018 01 05; 359(6371):86-90. Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete of HIV: Still a very long way to go, but progress continues. PLoS Med. 2017 Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. J Virol. 2017 12 01; 91(23). Teigler JE, Zelinskyy Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. Abdel-Mohsen Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers. S, An and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. AIDS Res Hum Nov; Trapecar Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. J Virol. 2017 11 15; 91(22). Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha BD, Martin J, Deeks S, Wolinsky SM, J, Martin Qi Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. Cell Rep. 2017 Oct 17; 21(3):813-822. Hiener B, Horsburgh BA, Eden JS, K, E, Stockenstrom Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. PLoS One. 2017; 12(8):e0183357. Booiman T, Prins M, Franceschi C, Deeks SG, Winston A, Reiss P, Kootstra NA, Co-morBidity in Relation to Aids S, [Hunt PW](https://profiles.ucsf.edu/peter.hunt), Rupert A, of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Level as a Marker of HIV Persistence and Low-Level Viral Replication. J Infect Peripheral T Follicular Helper Cell Function in HIV Controllers. J Virol. 2017 07 15; 91(14). Buranapraditkun S, Pissani F, Teigler Schultz BT, Alter G, Marovich M, Robb ML, Eller MA, Martin J, of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. Sci Rep. 2017 Johnson JR, Hull PA, Montano M, Sakane N, V, Mucosal Immunity in HIV-Infected Patients - Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Res cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight. 2017 HIV-1 outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. Virology. 2017 07; 507:135-139. Charlins monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV. 2017 06; 4(6):e251-e259. Caniglia EC, Cain LE, R, Abgrall S, Mugavero MJ, Hern\u00e1ndez-D\u00edaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, [Mathews WC](https://profiles.ucsd.edu/william.mathews), Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger JA, Costagliola D, Saag M, Hern\u00e1n MA, HIV-CAUSAL Collaboration, Centers for AIDS Research Network of Integrated Clinical Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. 15; of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies. J Infect Dis. in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression. J Virol. 2017 J, Kaidarova Z, X, Wu S, Anastos K, Crystal H, cross-sectional HIV incidence assay results from dried blood spots and plasma. and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Ishai D, Takx RA, Hur S, Kaiser Y, Pampaloni M, Rupert A, Hsu D, Sereti I, T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017 01 13; 7:40354. Tauriainen J, Scharf L, Frederiksen Inflammation, and Coagulation in Microvascular Disease in HIV. J Am Heart Assoc. 2016 12 20; 5(12). Sinha A, Ma can inhibiting an antiviral mechanism advance an HIV cure? J Clin Invest. 2017 does exposure to early diseases accelerate the age-related decline in health? Ann N Y Acad Sci. A, Fuldner R, P, emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 2016 12 01; 45(6):2038-2049. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodr\u00edguez B, Cozzi-Lepri A, Boswell SL, I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Egger M, Mugavero S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hern\u00e1n MA, Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated control. Hum Immunol. 2017 Feb; 78(2):179-184. Nititham J, Gupta Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis. Oct; 3(4):ofw189. Delagr\u00e8verie the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology. 2016 08 24; 13(1):59. Wacleche independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016 08 24; 30(13):2065-74. Hsu DC, Ma YF, Hur S, Li and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected during acute HIV-1 infection. Nat Med. 2016 09; 22(9):1043-9. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Capoferri AA, of Early Antiretroviral Therapy for HIV Infection: How Early is Early and the HIV Reservoir Size during Antiretroviral PLoS Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell. 2016 Aug 11; 166(4):1004-1015. Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal D, Nganou-Makamdop RA, Connors M, Moir S, Schacker LAG-3 Contribute to Persistence Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 08; 22(8):839-50. Deeks SG, Lewin D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, International AIDS Society Towards a Cure Working Group, Alter G, [Auerbach J](https://profiles.ucsf.edu/judith.auerbach), Autran B, Barouch GM, Eholi\u00e9 S, Eyal N, Fidler S, Garcia Grossman C, TJ](https://profiles.ucsf.edu/timothy.henrich), Jefferys R, Kiem A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen Opin HIV AIDS. DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. AIDS. 2016 06 19; 30(10):1511-20. Khoury G, Transcription and Reactivation. PLoS Pathog. 2016 06; 12(6):e1005677. Abdel-Mohsen M, Chavez Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Jun 01; 72(2):214-21. Caniglia LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, [Mathews WC](https://profiles.ucsd.edu/william.mathews), Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hern\u00e1n MA, Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? Acquir Immune Defic Syndr. Sajadi MM, Tindle HA, Justice AC, Freiberg for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral PLoS One. 2016; 11(5):e0155100. Grund B, Baker JV, Deeks SG, Wolfson J, A, Phillips A, CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Res Hum Retroviruses. 2016 08; 32(8):791-800. Ganesh A, Lemongello D, Lee E, Peterson J, McLaughlin BE, Ferre AL, Gillespie GM, Fuchs Cholesterol Despite With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. J Infect Dis. 2016 07 15; 214(2):216-25. Cobos Jim\u00e9nez V, Wit J, Prins M, Leeuwen Booiman T, Deeks Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. J Infect Dis. 2016 07 01; 214(1):73-9. Phillips AN, Cambiano S, Becker S, Mucosal Immunity in HIV-Infected Patients Mucosal Immunity in HIV-Infected Patients TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog. 2016 Jan; 12(1):e1005349. Reed KB, Clayton Mitchell reservoirs: where and how to target them. Nat Rev Microbiol. 2016 01; 14(1):55-60. Churchill reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015 patients shows no correlation between T-cell activation and anelloviruses levels. J Clin Virol. 2015 Nov; 72:106-13. Li L, Deng X, 2015 10 01; 1:15035. Deeks SG, Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. Erad. 2015; genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proc Natl Rogers K, MS, Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC Mortality to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. in two HIV-1-infected persons homozygous for 2015 [Henrich Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. J Immunol. 2015 01; JN](https://profiles.ucsf.edu/jeffrey.n.martin), Deeks SG, the National Advisory Committee on Immunization's Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. Can Commun Dis Rep. 2015 Apr 20; 41(Suppl 3):11-13. Ismail S, Deeks S, National Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr; 16 Suppl 1:37-45. Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. left behind? J Neurovirol. 2015 Jun; 21(3):322-34. Brew BJ, Robertson EJ, M, Crowe SM, Cysique LA, Deeks S, Garcia JV, Gelman B, Gray LR, Johnson T, Joseph J, Margolis DM, Mankowski Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. J Infect Dis. 2015 Aug 15; 212(4):596-607. von Stockenstrom S, Odevall P](https://profiles.ucsf.edu/peter.bacchetti), Killian M, Faria NR, P, Albert Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS. 2015 Feb 20; 29(4):411-20. Abdel-Mohsen M, Wang C, Effect therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. Int J Epidemiol. 2015 Feb; 44(1):251-63. Geng EH, [Neilands TB](https://profiles.ucsf.edu/torsten.neilands), Thi\u00e8baut R, Bwana MB, D, Moore RD, Zannou DM, Althoff KN, Lim PL, Nachega F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, [Hunt mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol. 2015 Apr; 89(7):3723-36. Clayton KL, Douglas-Vail MB, myocardial infarction in HIV disease in a predominantly male cohort. Res Int. 2015; 2015:246870. Badejo Tracy JV, Rimland D, Butt AA, Gordon AJ, Rinaldo response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015 Jan 15; 517(7534):381-5. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015 Jan 02; 29(1):43-51. [Somsouk M](https://profiles.ucsf.edu/ma.somsouk), treated HIV-infected individuals with incomplete CD4+ T Liegler T, Lifson J, Piatak M, During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California. J Infect Dis. 2015 Jun 01; 211(11):1757-60. Hollingsworth TD, in HIV-infected patients on K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan RW, Martin BP, Sinclair E, Deeks in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J Infect Dis. 2015 Apr 01; 211(7):1068-75. Sanchez T cell activation are associated with HIV DNA in resting CD4+ T T cell (T(SCM)) subset is associated with improved prognosis in chronic HIV-1 infection. J Virol. 2014 of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014 Sep 10; 28(14):2097-107. Petersen ML, Tran L, Geng EH, Reynolds Limited infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in individuals. of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS. 2014 Jul 31; 28(12):1791-6. Borges \u00c1H, Weitz JI, Collins G, CD4 and CD8 T cells in treated and untreated HIV disease. AIDS. 2014 Jul progress? Lancet. 2014 Jul mediates antibody-dependent CD4(+) T cells. Immunol Cell Biol. 2014 transcription in CCR5-32 heterozygotes during suppressive antiretroviral therapy. J Infect Dis. 2014 Dec 01; 210(11):1838-43. Wang C, Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses. 2014 Jul; 30(7):654-64. Tandon R, Chew GM, Byron lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Robinson Fine RW, Jacobson JM, Landay AL, Douek SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT, AIDS Clinical low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS look at hepatitis C clearance in HIV controllers: a response. AIDS. 2014 May 15; 28(8):1241-2. Asher AK, coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, [Hunt PW](https://profiles.ucsf.edu/peter.hunt), Plants CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. Clin Infect Dis. 2014 Aug 15; 59(4):596-600. Symons J, Vandekerckhove L, H\u00fctter G, Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014 Oct 15; 210(8):1228-38. [Hunt PW](https://profiles.ucsf.edu/peter.hunt), Sinclair E, Rodriguez B, Shive Robinson J, JN](https://profiles.ucsf.edu/jeffrey.n.martin), SG, inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis. 2014 Jul 15; 59(2):279-86. Gopal S, Patel Achenbach CJ, Napravnik S, Burkholder GA, Mathews WC, Rodriguez B, Deeks SG, Mayer KH, T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS One. 2014; 9(4):e92934. Siewe B, Wallace J, Rygielski HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant. 2014 May; 14(5):1136-41. [Stock PG](https://profiles.ucsf.edu/peter.stock), Barin B, Lee TH, [Busch M](https://profiles.ucsf.edu/michael.busch), Deeks SG, for Solid Organ Transplantation in with HLA class I correlates with control of HIV-1 infection. PLoS Genet. 2014 Mar; 10(3):e1004196. Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, Bream JH, CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 01; 210(3):374-82. [Lee SA](https://profiles.ucsf.edu/sulggi.lee), recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014 Aug 01; 210(3):383-91. Byakwaga H, Boum Y, Huang Y, Muzoora [Weiser SD](https://profiles.ucsf.edu/sheri.weiser), Bennett J, on CD8+ T cell CD57 expression is distinct from that of and dimethylarginine are associated with pulmonary arterial hypertension in HIV 2014 the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints. J Virol. 2014 May; 88(9):4668-78. Payne RP, Branch S, Kl\u00f8verpris Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste R, Walker BD, Brander inflammation during suppressive ART. J Acquir HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology. 11:10. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS. HIV-1. AIDS. 2014 Jan Heredia Davis Amin MN, function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014; to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014; 9(1):e85516. A, Lambotte O, ANRS CO18 HIV Controllers Cohort, Cascade Collaboration in Eurocoord, SCOPE Cohort, International HIV Controllers percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS mature NK cells with impaired effector function during HIV-1 infection. Retrovirology. 2013 Dec 18; the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. Mar; characterization as a method to quantify reservoir size during curative interventions. J Infect Dis. 2014 May 15; 209(10):1613-7. Burbelo HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A. 2013 Shao W, [Hunt PW](https://profiles.ucsf.edu/peter.hunt), [Somsouk M](https://profiles.ucsf.edu/ma.somsouk), Wylie W, Douek DC, Loeb Hoh R, Poole control and Crohn disease. Proc Natl Acad Sci U S A. 2013 17; Kulkarni S, Qi Y, O'hUigin C, Pereyra F, Ramsuran V, McLaren P, Fellay J, Nelson G, Chen H, [Liao W](https://profiles.ucsf.edu/wilson.liao), Bass S, Apps R, Gao X, Yuki Y, Lied A, Ganesan A, [Hunt B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS. 2013 Nov 13; 27(17):2691-6. Asher AK, [Santos Antibodies cure. Nature. 2013 Nov 14; of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol. 2014 Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013 Oct 17; 39(4):633-45. Deeks SG, Expression of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013 Oct 16; 10:106. Abdel-Mohsen M, Raposo RA, Deng after HIV-associated lymphoma. AIDS. 2013 Sep 24; 27(15):2365-73. Gopal S, and RNA in gut-associated lymphoid tissue of HIV-infected controllers and the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. 2013 repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One. 2013; 8(8):e71879. Mexas Oct; presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013 Aug 21; 105(16):1221-9. Gopal S, common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 PLoS Pathog. 2013; 9(7):e1003515. McLaren PJ, Coulonges Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Herbeck Kathiresan S, GD, O, Luo M, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou CA, presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS. of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis. 2013 Oct 15; 208(8):1212-20. [Yukl Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013 Oct is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013 Jul 10; 5(193):193ra91. and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. Jul; CD4 T cell responses with HIV immune control. Nat Med. 2013 Jul; 19(7):930-3. Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, Sidney J, Kranias G, Flanders MD, Lindqvist M, Kuhl B, Alter detecting HIV persistence during potentially curative interventions: a study of the Berlin JS, [Keating S](https://profiles.ucsf.edu/sheila.keating), HIV-infected individuals with incomplete CD4+ T-cell Hayes McLaughlin B, Landay level on HIV control. Science. 2013 Apr 05; 340(6128):87-91. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, Deeks SG, Pereyra F, a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013 Jun 15; 381(9883):2109-17. Katlama C, Deeks SG, Autran B, Rouzioux Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013 Mar 27; 27(6):973-979. Rodger AJ, Lodwick R, Schechter R, Paredes R, Bakowska E, Engsig FN, Phillips A, immunodeficiency virus type 1-infected RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), Deeks analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013 Feb; 9(2):e1003174. Eriksson Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):149-63. Justice Althoff KN, Gebo R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Med. 2013 Jan; decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood. 2013 Feb 14; 121(7):1124-35. Leeansyah E, Ganesh A, surface molecule represents CD8 T cells with dissimilar effector function during HIV-1 for mtDNA as a biomarker of innate immune activation in HIV infection. PLoS One. against HIV-1 variants isolated from Immune Defic Syndr. 2012 Nov 01; Underwood assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune 2012 results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013 Jan 15; 207(2):213-22. Azzoni L, Foulkes AS, Papasavvas E, of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013 Jan; in the simian immunodeficiency virus-infected rhesus macaque: a pilot the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain. N Engl J Med. 2012 Sep 27; 367(13):1246-54. in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC revealed leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS. 2012 Sep 24; 26(15):1869-78. Tomescu C, Duh FM, Hoh R, Viviani a \"universal antiretroviral therapy\" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/L in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7. Geng EH, Hare CB, JO, and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob expression is inversely associated with chronic immune activation in HIV-1 infection. PLoS One. 2012; functions in human immunodeficiency virus (HIV)-infected and cure: a global scientific strategy. Nat Rev Immunol. 2012 07 20; 12(8):607-14. International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud M, Poli JP, Rouzioux C, M, A, Lint HIV. Nature. 2012 Jul 18; and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay JD, of HAART on alternative reading frame immune responses over the course of HIV-1 infection. PLoS One. 2012; 7(6):e39311. Champiat Hasenkrug AM, HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet. 2012 Oct 01; 21(19):4334-47. McLaren PJ, Ripke RL, D, DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI, disease in HIV-infected adults. J Infect Dis. 2012 retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012 May 02; 4(132):132ra53. Scholler M, Riley JL, Deeks SG, RT, disease, and biomarkers of inflammation, altered coagulation, and monocyte Clin Infect Dis. 2012 Jul; 55(1):126-36. Armah KA, McGinnis K, J, Gibert Bryant KJ, [Goetz M](https://profiles.ucla.edu/matthew.goetz), Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. with subclinical carotid artery disease among HIV-infected women. J Infect Dis. 2012 Jun 15; 205(12):1788-96. Parrinello in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis. 2012 Jun; 205(11):1730-8. Tassiopoulos K, receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood. 2012 Apr 12; 119(15):3469-77. Baum PD, Young JJ, Schmidt D, Zhang genetic variants that protect against HIV-1 disease. PLoS Genet. 2012 Feb; 8(2):e1002514. Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV, Martin MP, Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012 Apr; 54(7):984-94. Justice AC, Freiberg Tracy R, disease. Cell Stem Cell. 2012 Feb 03; 10(2):137-47. during antiretroviral therapy: how low is low enough? Clin Infect Dis. 2012 not associated with carotid artery intima-media thickness in (GM) and FcR genes and the host control of human immunodeficiency virus replication. Hum virus-infected patients without coronary J Cardiol. 2012 01; 109(5):742-7. [Hsue cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood. 2012 Jan 19; 119(3):745-55. Eriksson T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral 2011 polymorphism are associated with plasma CD14 Q, of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011 Nov; 53(10):1008-14. Geng EH, Kahn JS, Chang OC, Hare CB, the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012 May; 28(5):469-77. Plaeger SF, Collins BS, are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011 Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, [Hunt PW](https://profiles.ucsf.edu/peter.hunt), -chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African suppressive cART. Immun. 2012 Jan; 13(1):83-93. Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A, Chua K, Stewart G, Deeks S, Bangsberg DR, Muzoora C, Cameron PU, Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, RG, Napravnik S, Thorne J, Moore RD, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the Infect Dis. 53(9):927-35. Mugavero MJ, Napravnik S, Cole SR, Crane HM, Kitahata MM, Willig JH, Moore RD, Deeks SG, Saag MS, Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011 care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS effectiveness the mathematics of antiviral agents for HIV. Sci Transl Med. 2011 Jul products predicts outcomes of patients with HBV Demino Kleiner DE, cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection. PLoS One. 2011; 6(6):e21190. Kitchen abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011 of sample size dogma to perform innovative translational research. Sci Transl Med. humans. PLoS One. 2011; Rosenberg activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol. 2011 Jul; [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), Spotts G, Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods. 2011 of HLA-C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495-8. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, [Hunt P](https://profiles.ucsf.edu/peter.hunt), Deeks SG, Telenti A, Pereyra F, Goldstein D, B, Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011 in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 01; 203(7):960-8. Hatano H, Hayes TL, Dahl HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood. 2011 May 12; 117(19):5142-51. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, Bailey M, Gorochov G, Duvivier C, Carcelain G, Kelleher AD, Simon A, Meyer L, HIV-infected women. Atherosclerosis. HIV-infected patients. AIDS. 2011 Mar 13; 25(5):651-7. Duprez DA, Neuhaus Tracy in HIV elite controllers is associated with T-bet expression. Blood. 2011 Apr 07; 117(14):3799-808. Hersperger A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One. 2011 Jan 31; carotid intima-media thickness in HIV-infected persons. Clin levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15; 203(6):780-90. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen HIV-1-protective single-nucleotide polymorphism 35 kilobases upstream of the HLA-C expression. Virol. Corrah TW, Goonetilleke Kopycinski may contribute to viral persistence in HIV controllers. Clin Infect Dis. 2011 Mar 01; 52(5):681-7. predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011 Feb 15; 203(4):452-63. Kaplan HIV progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood. 2011 Feb 17; at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. B, A, Moore RD, Justice AC, North American AIDS Cohort Collaboration on Research and Design. drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010 Nov 27; 24(18):2835-40. Bangsberg DR, HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol. determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, J, Schaefer T, Verma P, Toth [Block B](https://profiles.ucsf.edu/brian.block), Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins S, Altschuler EL, Ambardar S, Anastos Anderson Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi Garcia E, Garmon Gathe JC, Gaultier CR, Gebre TD, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian JT, Kogelman L, Kojic EM, M, H](https://profiles.ucsf.edu/harry.lampiris), M, Lederman MM, Lee AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, VC, P, Mesa G, Metroka CE, Meyer-Olson D, Miller K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson AM, CS, [Richman DD](https://profiles.ucsd.edu/douglas.richman), Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak Sterman FL, Stone Stone DR, Tambussi G, to HAART, by age and regimen class. AIDS. 2010 Oct 23; Althoff Napravnik S, Tedaldi E, Klein MB, Gebo KA, North American AIDS Cohorts Collaboration on Research, inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91. Cummins cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop integrase inhibitor-based antiretroviral at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS. 2010 Jul 31; 24(12):1897-905. Ho JE, blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of controllers. J 2010 Oct; elite controllers do what they do? Clin Infect Dis. 2010 Jul Antiretroviral infection. Lancet. 2010 Jul 03; presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010 Jun 01; Eron JJ, a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health. 2010 Jun; 15 Suppl the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36. Favre T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS. of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature. 2010 May 20; 465(7296):350-4. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS. 2010 Apr 24; 24(7):941-5. [Hecht systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS. 2010 Apr 24; 24(7):1001-5. Probasco for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood. 2010 Apr 15; cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010 Jan function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 09; 121(5):651-8. Choi more to save more: interventions to promote adherence. Ann Intern Med. 2010 Jan and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet. 2009 Dec; 41(12):1290-4. Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), Margolick J, Goedert A, Deeks SG, Walker BD, on diastolic function and left ventricular mass. treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90. Deeks Rodriguez B, Sterling TR, Kirk GD, Napravnik continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009 Oct 23; of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009 Sep 29; 4(9):e7196. [Rosenblum impaired endothelial function in treated and suppressed HIV-infected AIDS. 2009 24; 23(15):2021-7. [Hsue Wu by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS. 2009 Sep 24; 23(15):1965-70. Snyder-Cappione JE, Carvalho KI, Kuylenstierna and infection prematurely age the immune system. J Clin Invest. 2009 Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009 Sep-Oct; of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo Nov; 26(11):2617-26. Jha EC, Wachter DJ, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), Deeks SG, virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses. 2009 Aug; 25(8):795-802. Huang W, Toma virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol. 2009 Sep; collaboratory. Science. 2009 Jun 05; 324(5932):1264-5. Murphy A, antiretroviral therapy, and immunodeficiency in HIV-associated abnormal CD8+ T cell activation and low CD4+ T cell counts of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85. Jiang W, Lederman MM, [Hunt P](https://profiles.ucsf.edu/peter.hunt), Sieg K, Rodriguez B, Landay A, Martin J, Sinclair E, of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26. Kitahata MM, Gange Abraham JN](https://profiles.ucsf.edu/jeffrey.n.martin), Rodriguez Kirk GD, Napravnik SE, Crane HM, McKaig RG, Lau B, Freeman AM, cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009 Mar 15; 48(6):787-94. Kelley CF, Kitchen CM, [Hunt PW](https://profiles.ucsf.edu/peter.hunt), Rodriguez Kitahata antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9. Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, recovery with antiretroviral therapy: more than the sum of the parts. Clin Infect Dis. 2009 Feb 01; 48(3):362-4. related morbidity. BMJ. 2009 Jan co-evolution gp120 and gp41 during and after enfuvirtide treatment. Comput Stat Data Anal. 2009 Jan 15; 53(3):766-775. Kitchen CM, Chem. 2009 Mar 13; X, Schweneker HIV-1 in elite controllers: a potential correlate of immune control. Blood. 2009 Apr 113(17):3978-89. Ferre the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Jan; of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008 Oct 18; 22(16):2097-106. Petersen ML, van der Laan MJ, dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic to modulate CSF HIV-1 infection: results of a pilot study. Neurology. 2008 Aug 12; Probasco doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008 Jul 30; 3(7):e2783. Parienti Das-Douglas and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS. effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008 Apr; 14(4):413-20. VC, Delmar J, Eron J, Clark RA, responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008 Jun; 82(11):5398-407. cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008 Jan 01; 197(1):126-33. [Hunt origin. 2008; 13(3):369-74. [Price Hoh R, cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS. 2007 Nov 12; 21(17):2363-5. Barker E, Martinson J, candidate clinical trials. Stat Med. 2007 Nov 10; 26(25):4578-601. Petersen ML, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, BK, for estimating time-varying effect modification. Am J Epidemiol. 2007 Nov 01; 166(9):985-93. controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007 Sep; 27(3):406-16. cell responses following long-term cryopreservation. J Immunol Methods. 2007 Sep 30; 326(1-2):93-115. profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response Gag to Pol. for 'deep salvage' trials in advanced HIV infection. AIDS. 2007 Jul 31; 21(12):1503-6. Lederman MM, Miller against HIV-1. Nat Genet. 2007 Jun; 39(6):733-40. Martin Qi Y, Gao X, Yamada E, Pereyra JJ, S, enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007 Apr; 81(7):3240-50. Ray N, assay with tuberculin skin testing in HIV-infected individuals. Am J the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. Haas DW, Hogg RS, Horberg MA, Jacobson LP, Kirk MB, [Martin JN](https://profiles.ucsf.edu/jeffrey.n.martin), McKaig RG, Rodriguez B, antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study Riddler of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis. 2007 Feb 01; 195(3):387-91. Deeks SG, Lu J, Hoh R, gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1260-6. Kitchen HIV patients is associated with increased cytomegalovirus-specific T-cell responses. a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71. Brenchley JM, Price DA, Schacker Kazzaz Z, Bornstein E, Lambotte on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006 Dec 15; 194(12):1686-96. Spudich infection: are acute and chronic HIV infection different diseases? J Infect Dis. 2006 Dec A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5. Ahuja SK, Aiuti F, Berkhout Korber B, Lederman MM, C](https://profiles.ucdavis.edu/chris.miller), Stevenson M, of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis. 2006 Predictive plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. HIV-1-infected patients: results of a 2006 Sep; 1 gp41 assays for detecting HIV-1-infected patients with detectable 2006 Oct 01; 194(7):926-30. [Hunt PW](https://profiles.ucsf.edu/peter.hunt), differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006 Jul 21; Nomura LE, The risk of treatment versus the risk of HIV replication. Lancet. 2006 Jun 17; and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol. 2006 Jun; SD, Squires S, Deeks S, Centers for View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16645578) Mentions: [2](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/16645578/citedby/) Translation: [Humans] - The independent effect of drug resistance on T cell activation in HIV infection. AIDS. 2006 Mar 21; 20(5):691-9. [Hunt PW](https://profiles.ucsf.edu/peter.hunt), Deeks SG, Bangsberg DR, Moss R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet. 2006 reverse transcriptase inhibitors explained by virological Virology. 2006 30; 347(1):117-26. Jordan KA, Furlan SN, Gonzalez VD, Karlsson AC, Quigley MF, Deeks SG, study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. Antivir Ther. 2006; 11(3):315-9. Beatty G, [Hunt adults with genotypically proven antiretroviral-resistant HIV infection. J infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis. 2005 Nov 02; parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. 2005 Nov; protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005 Oct 14; 19(15):1575-85. Legrand FA, Abadi J, Jordan KA, GJ, analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther. 2005 Aug 18; 2:6. multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS. 2005 proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. McEvers K, Elrefaei M, [Norris P](https://profiles.ucsf.edu/philip.norris), of a ritonavir/lopinavir-based regimen. AIDS. 2004 Sep 24; Friend 2004 Sep; in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood. 2004 Dec 01; 104(12):3672-8. Aandahl EM, Quigley CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004 Aug 01; 173(3):2184-9. Elrefaei M, McElroy MD, Preas inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004 Jul 01; periods of intermittent and persistent low-level viremia. AIDS. 2004 Apr 30; 18(7):981-9. Karlsson Immune point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004 Aug 15; 104(4):942-7. Deeks SG, Kitchen CM, Liu L, Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004 May; 53(5):696-9. assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004 AIDS virus infection: good, bad, or both? J Clin associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004 Jan 15; 189(2):312-21. Deeks human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the flow cytometry assays for the enumeration of T Methods. 2003 Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003 Oct 01; 188(7):1001-8. Jiang H, Deeks SG, Kuritzkes DR, count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003 Sep 05; 17(13):1907-15. [Hunt PW](https://profiles.ucsf.edu/peter.hunt), High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003 Sep 05; R, Guzman D, with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003 May 15; count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):917-9. [Jacobson of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003 Feb 14; 17(3):361-70. Deeks Multiple of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003 Jan 03; 17(1):53-63. Anton PA, Mitsuyasu RT, Deeks SG, Scadden Huang to CD4(+) T cell number in individuals. of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia combination antiretroviral therapy. Mol Ther. 2002 Jun; 5(6):788-97. Deeks SG, Wagner B, Anton DT, Huang C, Macken C, activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease Deeks SG, JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002 in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002 safety, and antiretroviral activity of tenofovir disoproxil fumarate benefit despite low-level viremia: reassessing definitions of success or failure. JAMA. to structured treatment interruption after virological failure. AIDS. 2001 Jul 06; 15(10):1251-9. [Price recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):517-23. Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, transcriptase inhibitor resistance. J combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001 15; 344(7):472-80. Deeks preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. AIDS. 2001 Jan 26; Liegler 7(1):73-9. Napolitano LA, Grant RM, Deeks SG, Schmidt D, Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000 Dec 22; 14(18):2877-87. Parkin NT, Deeks Wrin adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells subjects. Blood. 2000 Aug 01; 96(3):785-93. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000 virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. Infect Dis. 2000 Mar; 181(3):946-53. Deeks SG, Barbour JD, type 1-associated hematosuppression by effective antiretroviral therapy. Clin Dis. 2000 30(3):504-10. Huang SS, with antiretroviral therapy: a randomized controlled trial. 22-29; 282(24):2305-12. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, S, 104 isolates in British Columbia, 1997-1998. Can Commun Dis Rep. 1999 Aug 01; 25(15):129-33. Buxton J, Fyfe M, King A, Deeks R, 1999 30; fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 13(9):1051-61. Staprans regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. Deeks SG, Hellmann NS, Grant cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999 Apr 16; 13(6):F35-43. Deeks SG, [Hecht FM](https://profiles.ucsf.edu/frederick.hecht), Swanson M, Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis. 1999 Apr; 28(4):840-6. Deeks S, De Serres Boulianne HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999 Jan; Hellerstein Cesar 1998 Nov 15; 24(22):177-8; discussion 178-9. Deeks Ellis intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) Sep; saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998 Jul 09; 12(10):F97-102. Deeks SG, Grant RM, Beatty GW, Horton problems. JAMA. 1998 May Conference Retroviruses & Opportunistic Infections. Interview by Ron Baker. Newsline People AIDS Coalit N Y. 1998 \"failure\": interview with Steven Deeks, M.D., San Francisco General Hospital. Interview by John S. James. AIDS Treat News. 1998 Feb 20; (No Practical issues regarding the use of antiretroviral therapy for HIV infection. West J Med. 1998 Feb; adefovir dipivoxil, a novel anti-human immunodeficiency adults: a disease in Canada, 1995-1996. Can Commun Dis Rep. 1997 Aug 15; 23(16):121-5. Deeks S, Kertesz D, Ryan A, human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997 Aug; 176(2):514-7. Deeks SG, Coleman clinicians. JAMA. 1997 Jan 08; 277(2):145-53. Deeks SG, Smith study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J Med. 1997; 28(1-2):108-28. Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, Lang W, Mimura symptomless HIV-1 infection. Lancet. 1996 Dec 07; 348(9041):1547-51. to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract (1995). rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res. 1988 Feb; 174(2):448-60. "}